



General Assembly

January Session, 2025

Proposed Bill No. 5485

LCO No. 833



Referred to Committee on INSURANCE AND REAL ESTATE

Introduced by:

REP. LUXENBERG, 12th Dist.

**AN ACT ESTABLISHING A CAPTIVE INSURANCE COMPANY TO
ADMINISTER A BULK PURCHASE AND DISTRIBUTION OF
GLUCAGON-LIKE PEPTIDE-1 PRESCRIPTION DRUGS TO
QUALIFYING INDIVIDUALS IN THIS STATE TO TREAT OBESITY.**

Be it enacted by the Senate and House of Representatives in General Assembly convened:

- 1 That title 38a of the general statutes be amended to establish a captive
- 2 insurance company, which shall be supported by the appropriation of
- 3 the sum of ten million dollars to said captive insurance company, from
- 4 the General Fund, for the fiscal year ending June 30, 2026, for the
- 5 purpose of (1) bulk purchasing glucagon-like peptide-1 receptor
- 6 antagonist prescription drugs from drug manufacturers, and (2)
- 7 distributing such prescription drugs to covered persons in this state who
- 8 satisfy a means-tested qualification process and demonstrate an
- 9 inability to obtain such prescription drugs from such covered person's
- 10 health insurer to treat obesity.

Statement of Purpose:

To establish a captive insurance company, which shall be supported by the appropriation of the sum of ten million dollars to said captive insurance company, from the General Fund, for the fiscal year ending

June 30, 2026, for the purpose of (1) bulk purchasing glucagon-like peptide-1 receptor antagonist prescription drugs from drug manufacturers, and (2) distributing such prescription drugs to covered persons in this state who satisfy a means-tested qualification process and demonstrate an inability to obtain such prescription drugs from such covered person's health insurer to treat obesity.